22,500 Shares in Nuvalent, Inc. $NUVL Purchased by Cantor Fitzgerald L. P.

Cantor Fitzgerald L. P. acquired a new stake in Nuvalent, Inc. (NASDAQ:NUVL) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 22,500 shares of the company’s stock, valued at approximately $1,946,000.

A number of other large investors also recently bought and sold shares of NUVL. Aster Capital Management DIFC Ltd purchased a new position in Nuvalent during the third quarter worth about $38,000. Eastern Bank purchased a new stake in shares of Nuvalent in the 3rd quarter valued at approximately $52,000. Persistent Asset Partners Ltd acquired a new position in shares of Nuvalent in the 2nd quarter worth approximately $88,000. PNC Financial Services Group Inc. lifted its holdings in shares of Nuvalent by 38.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,632 shares of the company’s stock worth $125,000 after acquiring an additional 451 shares during the last quarter. Finally, Compass Wealth Management LLC purchased a new position in shares of Nuvalent during the 3rd quarter worth approximately $172,000. Institutional investors and hedge funds own 97.26% of the company’s stock.

Nuvalent Stock Down 0.1%

Shares of NUVL opened at $97.93 on Friday. The company has a market cap of $7.12 billion, a P/E ratio of -16.74 and a beta of 1.32. Nuvalent, Inc. has a fifty-two week low of $55.53 and a fifty-two week high of $113.01. The firm’s 50 day moving average price is $102.97 and its 200 day moving average price is $96.94.

Analysts Set New Price Targets

Several analysts recently weighed in on NUVL shares. Guggenheim boosted their target price on Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. UBS Group restated a “buy” rating on shares of Nuvalent in a research report on Wednesday, December 17th. Wedbush reaffirmed an “outperform” rating and issued a $125.00 price objective (up from $120.00) on shares of Nuvalent in a research note on Monday, November 17th. JPMorgan Chase & Co. cut their price objective on Nuvalent from $147.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Finally, Cantor Fitzgerald increased their target price on Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Fifteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Nuvalent presently has an average rating of “Moderate Buy” and a consensus price target of $138.67.

Insiders Place Their Bets

In other news, insider Henry E. Pelish sold 2,664 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $97.17, for a total transaction of $258,860.88. Following the sale, the insider owned 65,888 shares of the company’s stock, valued at approximately $6,402,336.96. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Durant Turner sold 4,236 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $412,247.52. Following the completion of the sale, the insider owned 58,311 shares in the company, valued at approximately $5,674,826.52. The trade was a 6.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 69,379 shares of company stock valued at $6,940,982. Corporate insiders own 10.20% of the company’s stock.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.